Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
3 papers
Recent·Most cited
J. Boumelha, A. de Castro, N. Bah…·J. Downward
The paper identifies KRAS-induced COX-2 as a driver of immunotherapy resistance in lung cancer through CRISPR/Cas9 screening and shows targeting COX-2 enhances immune checkpoint blockade efficacy.
E. Mugarza, F. van Maldegem, J. Boumelha…·J. Downward
KRASG12C inhibition enhances anti-tumour immunity in immunogenic lung cancers by upregulating interferon signaling through Myc repression, but only synergizes with immune checkpoint blockade in highly immunogenic models.
N. M. Sodir, L. Pellegrinet, R. M. Kortlever…·G. I. Evan
This study shows that acute Myc suppression in adult mice prevents KRasG12D-driven lung and pancreatic cancers with minimal side effects when applied metronomically.